Post-Market Clinical Follow-up Study of the REDAPT Monolithic Sleeveless Stem and Acetabular Components Devices Used for Hip Replacement Surgery.

Retrospective-prospective, single arm, multi-center study of subjects previously implanted
with the REDAPT Revision Femoral System Monolithic Sleeveless Stems and/or Acetabular
Components

Inclusion Criteria:

- Subject has undergone hip arthroplasty with the REDAPT Revision Femoral System
Monolithic stem and/or cup Acetabular Components with implantation prior to date of
Site Initiation Visit to active study.

- Subject required surgery with REDAPT device chosen for the following indications:

i. Complex Primary THA ii. Conversion THA iii. Periprosthetic fracture iv. Revision
THA

- Subject is willing to consent to and to follow the study visit schedule (as defined in
the study protocol and informed consent form), by signing the IRB/EC approved informed
consent form.

- Subject is willing and able to participate in required follow-up visits at the
investigational site and to complete study procedures.

Exclusion Criteria:

- Subject surgery with REDAPT device chosen due to S/P spacer placement infection.

- Subject, in the opinion of the principal investigator (PI), has an emotional or
neurological condition that would pre-empt their ability or willingness to participate
in the study including mental illness, mental retardation, drug or alcohol abuse.

- Subject is known to be at risk for loss to follow-up or failure to return for
scheduled visits.

- Subject is incarcerated or is pending incarceration.

- Subject enrolled in another clinical study that would affect the endpoints of the
study.